Previous Close | 42.55 |
Open | 42.58 |
Bid | 42.76 x 900 |
Ask | 43.40 x 1100 |
Day's Range | 41.97 - 42.78 |
52 Week Range | 32.87 - 54.44 |
Volume | |
Avg. Volume | 1,229,423 |
Market Cap | 6.126B |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.56 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for IONS
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH). The study met its primary endpoint at both doses (120 mg and 90 mg), achieving liver histologic improvement, and also met the important secondary endpoint of MASH resolution.